Results 11 to 20 of about 22,842 (183)
Effects of Sulfonylureas on Peroxisome Proliferator-Activated Receptor γ Activity and on Glucose Uptake by Thiazolidinediones [PDF]
Diabetes & Metabolism Journal, 2011 BackgroundSulfonylurea primarily stimulates insulin secretion by binding to its receptor on the pancreatic β-cells. Recent studies have suggested that sulfonylureas induce insulin sensitivity through peroxisome proliferator-activated receptor γ (PPARγ ...
Kyeong Won Lee +5 more
doaj +1 more source
Saudi Pharmaceutical Journal, 2016 The article titled “Can an oral antidiabetic (rosiglitazone) be of benefit in leukemia treatment?” written by Cetinkalp et al. and published in one of the recent issues of your journal was quite interesting (Cetinkalp et al., 2015). Here, we would like to emphasize some points. Pan et al.
Irfan Yavasoglu +2 more
openaire +3 more sources
CMHX008, a novel peroxisome proliferator-activated receptor γ partial agonist, enhances insulin sensitivity in vitro and in vivo. [PDF]
PLoS ONE, 2014 The peroxisome proliferator-activated receptor γ (PPARγ) plays an important role in adipocyte differentiation and insulin sensitivity. Its ligand rosiglitazone has anti-diabetic effect but is frequently accompanied with some severe unwanted effects.
Yue Ming +12 more
doaj +1 more source
PPAR Research, 2018 The peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist rosiglitazone inhibits NF-κB expression and endogenous neural stem cell differentiation into neurons and reduces the inflammatory cascade after spinal cord injury (SCI).
Qing-qi Meng +6 more
doaj +1 more source
Scientific Reports, 2017 Obesity-related albuminuria is associated with decline of kidney function and is considered a first sign of diabetic nephropathy. Suggested factors linking obesity to kidney dysfunction include low-grade inflammation, insulin resistance and adipokine ...
Martine C. Morrison +9 more
doaj +1 more source
Mediators of Inflammation, 2012 Peroxisome proliferator-activated receptors (PPARs) are shown to modulate the pathological status of sepsis by regulating the release of high mobility group box 1 (HMGB1), a well-known late proinflammatory mediator of sepsis.
Jung Seok Hwang +9 more
doaj +1 more source
Reproductive Biology and Endocrinology, 2009 Background Ovarian granulosa cells are the predominant source of estradiol and progesterone biosynthesis in vivo. Rosiglitazone, a synthetic agonist of the peroxisome proliferator-activated receptor gamma (PPAR gamma), is applied as the treatment of ...
Wang Yongwei +6 more
doaj +1 more source
Preparation and in vitro evaluation of enteric-coated tablets of rosiglitazone sodium
Saudi Pharmaceutical Journal, 2015 The aim of this study was to prepare the rosiglitazone sodium enteric-coated tablets and investigate its release rate. The rosiglitazone sodium enteric-coated tablet was prepared by single punch tablet press using substituted hydroxypropyl cellulose and ...
Xin-mei Pan +3 more
doaj +1 more source
Journal of Pharmacological Sciences, 2011 .: The discovery of endothelial progenitor cells (EPCs) provides us with a novel treatment strategy for complications requiring therapeutic revascularization and vascular repair.
Shengjie Xu +5 more
doaj +1 more source
Effect of rosiglitazone on HDL metabolism in subjects with metabolic syndrome and low HDL
Journal of Lipid Research, 2011 Treatment with the peroxisome proliferator-activated receptor γ agonist rosiglitazone has been reported to increase HDL-cholesterol (HDL-C) levels, although the mechanism responsible for this is unknown. We sought to determine the effect of rosiglitazone
John S. Millar +5 more
doaj +1 more source